Melanie De Almeida, Author at Labiotech.eu

News and Trends 30 Nov 2018

Update: UK Biotech Scores £5M Series A to Boost Next-Generation Cancer Antibodies

Update (30/11/2018): IGEM Therapeutics has increased the total raised in Series A to £5M (€5.6M) with the participation of two new investors, Alsa Holdings and UCL Technology Fund. The funding will…

November 30, 2018 - 2 minutesmins - By Melanie De Almeida

In Depth 14 Nov 2018

Taking Biotech to the Next Level with Laboratory Automation

Automation is slowly taking over our lives, ranging from smart homes to self-driving cars. With experiments becoming ever more complex and datasets more immense, a question that comes to mind:…

November 14, 2018 - 6 minutesmins - By Melanie De Almeida

News and Trends 13 Mar 2018

French Biotech Takes its Oral Diabetes Drug to Phase III

Update (13/03/2018): Poxel has started two more Phase III trials in Japan testing its drug for type 2 diabetes, imeglimin. This oral drug has shown potential to lower glucose levels thanks…

March 13, 2018 - 3 minutesmins - By Melanie De Almeida

In Depth 6 Feb 2018

CRISPR/Cas9: Could the Gene Editing Technology be the Future of Drug Discovery?

The emergence of CRISPR/Cas9 technologies has enabled almost unlimited gene editing opportunities. Not only could it be used as a therapeutic tool, the genome editing tool could kickstart a revolution…

February 6, 2018 - 9 minutesmins - By Melanie De Almeida

News and Trends 5 Sep 2017

UPDATE: Austrian Biotech receives €3.3M boost for its Chikungunya Vaccine

UPDATE (05/09/2017): Innovate UK has granted Themis £3M (€3.3M) to push its Chikungunya Vaccine towards Phase III. Originally Published 06/06/2017 Themis Bioscience will test its vaccine candidate against Chikungunya fever…

September 5, 2017 - 3 minutesmins - By Melanie De Almeida

News and Trends 26 Jul 2017

Update: Potential Breakthrough Treatment for Deadly Lung Disease Starts Phase IIb

Update (26/07/2017): Verona Pharma has dosed the first patients in the PhaseIIb with RPL554 in patients with chronic obstructive pulmonary disease (COPD). Results are expected in the second half of 2018.…

July 26, 2017 - 2 minutesmins - By Melanie De Almeida

News and Trends 20 Jul 2017

Update: Danish Psoriasis Drug Gets EU Approval Despite Suicide Links

Update (20/07/2017): The European Commision has granted LEO Pharma marketing authorization for Kyntheum (brodalumab), making it the first biologic drug that targets IL-17a. Published 22/05/2017 The EMA has taken up a…

July 20, 2017 - 3 minutesmins - By Melanie De Almeida

In Depth 11 Jul 2017

Regenerating the Body With Stem Cells – Hype or Hope?

When the Japanese researcher Shinya Yamanaka managed to reprogram adult cells into an embryonic-like state to yield induced pluripotent stem cells (iPSCs), this was supposed to herald a revolution in…

July 11, 2017 - 9 minutesmins - By Melanie De Almeida

Startup Scout 30 Jun 2017

This Danish Biotech Thinks it Can Tackle the Obesity Epidemic

Apart from boasting big players in the space of metabolic diseases including Novo Nordisk and Zealand Pharma, Copenhagen is a hotspot for research on obesity and diabetes. This week we…

June 30, 2017 - 2 minutesmins - By Melanie De Almeida

News and Trends 29 Jun 2017

New Drug for Neuropathic Pain Is Forging its Way through the Clinic

Pharmaleads has scored positive results in a first Phase I trial for its DENKI peptide PL265 to treat chronic neuropathic pain. The treatment of neuropathic pain commonly involves the prescription of opioids,…

June 29, 2017 - 3 minutesmins - By Melanie De Almeida

Interview 28 Jun 2017

Video: The Next Big Thing in Biotech according to Sofinnova’s Antoine Papiernik

Antoine Papiernik, Managing Partner at the famous European biotech VC Sofinnova, closed Refresh this year with a keynote on the next big thing in biotech. Papiernik has more than 20…

June 28, 2017 - 3 minutesmins - By Melanie De Almeida

More News! 27 Jun 2017

Green Biotech Enters Partnership to Advance the Infinite Recycling of Plastics

Carbios has teamed up with TechnipFMC in order to move Carbios' enzymatic recycling process for PET plastics from the laboratory to the pilot scale. French Carbios is looking to combat the…

June 27, 2017 - 2 minutesmins - By Melanie De Almeida

Startup Scout 23 Jun 2017

This Newly Founded French Biotech is All About Vaccines

This week we visited the biotech hub Lyon, where one of our top biotechs Imaxio has recently founded Osivax to advance the development of its innovative vaccine candidates. Mission: Osivax was formed as a spin-off…

June 23, 2017 - 1 minutemin - By Melanie De Almeida

Novartis Cardiovascular Canakinumab Phase III

News and Trends 22 Jun 2017

Novartis Scores Major Phase III Win with New Cardiovascular Drug

Novartis just announced that its anti-inflammatory drug, canakinumab, was able to clear a 10,000-plus patient Phase III trial for cardiovascular disease. Novartis most recently boasted impressive Phase III results for its AMD drug, RTH258, that…

June 22, 2017 - 2 minutesmins - By Melanie De Almeida

Interview 21 Jun 2017

Video: Can Synbio Cure Malaria? – Fireside Chat with Oxitec’s CEO Hadyn Parry

In our fireside chat with Hadyn Parry, Clara had the chance to hear all about Oxitec's exciting technology that could save us from Dengue and Zika. Oxitec's GM mosquitoes have the…

June 21, 2017 - 3 minutesmins - By Melanie De Almeida

Cell Medica Catapult Therapy TCR Acquisition

News and Trends 21 Jun 2017

British Biotech Tops up its Cancer Pipeline with New TCR Therapy

Cell Medica just acquired Catapult Therapy TCR, set up by UK's CGT Catapult, gaining the rights to its TCR therapy candidate to treat solid tumors. Cell Medica says it's all…

June 21, 2017 - 2 minutesmins - By Melanie De Almeida

News and Trends 20 Jun 2017

Novartis Tops Ophthalmology Blockbuster Eylea in Phase III Trials

Bayer's and Regeneron's blockbuster Eylea could be facing serious competition, as Novartis boasts with positive Phase III results for AMD. Novartis has been struggling on the age-related macular degeneration (AMD) market…

June 20, 2017 - 2 minutesmins - By Melanie De Almeida

Interview 19 Jun 2017

Video: “Biotech is still in its Infancy” – Keynote by Boston’s Prominent Biotech VC

We were very excited that David Berry, General Partner at Flagship Pioneering, opened Refresh earlier this month with a keynote on how far biotech has come. David has extensive experience…

June 19, 2017 - 2 minutesmins - By Melanie De Almeida

Startup Scout 16 Jun 2017

Meet the Swedish Biotech that is Set to Cure a Rare Kidney Disease

This week we visited the Scandinavian summer and had a look at the Swedish biotech Oxthera, which is developing cell- and enzyme-based therapies to treat hyperoxaluria. Mission: Stockholm-based Oxthera is currently…

June 16, 2017 - 2 minutesmins - By Melanie De Almeida

News and Trends 15 Jun 2017

UK-based VC Launches Massive $300M Fund to Fill Gap for Late-Stage Biotech

The UK-based VC Medicxi has raised a massive $300M (€268M) fund backed by Novartis and Google's Verily to invest in late-stage drug development. After the former life science branch of famous…

June 15, 2017 - 3 minutesmins - By Melanie De Almeida

Report: new Frontiers in Vaccinology

Listen to our podcast

View all sectors A-Z

Power your event with partnering to deliver attendee ROI. Learn more!

View all companies A-Z

Find new scientific partnerships. Create a free IN-PART account

View all countries A-Z

Report: The European Biotech Startup Ecosystem

Subcribe to our newsletter

Learn more about Inova, the leading platform for biopharma partnering

Report: new Frontiers in Vaccinology

Listen to our podcast

View all sectors A-Z

Power your event with partnering to deliver attendee ROI. Learn more!

View all companies A-Z

Find new scientific partnerships. Create a free IN-PART account

View all countries A-Z

Report: The European Biotech Startup Ecosystem

Subcribe to our newsletter

Learn more about Inova, the leading platform for biopharma partnering

About

Articles by Melanie De Almeida

Outsourcing in life science R&D today

Power your event with partnering to deliver attendee ROI.

Subscribe to our newsletter to get the latest biotech news!